V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Coherus Oncology Executive Compensation (FY25)

CHRS · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Dennis Lanfear
Latest say-on-pay support
=
May 27, 2026
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.

The Coherus Oncology brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
Data as of October 22, 2026Latest filing (8-K): June 1, 2026
4 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Coherus Oncology brief$1,500Get the executive brief
Velarion Member, one year
162 figures on this page: 160 cited to the filing that reported them, 2 calculated from figures it prints. See the citations
This company is not required to report a chief executive pay ratio.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Dennis Lanfear: $4,802,309 → $2,736,874 (43.0% lower)
Say-on-pay support: 54.3% → 87.1% (32.8 points higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Coherus Oncology's chief executive and what were they paid?
Dennis Lanfear, President, Chief Executive Officer and Chairman of the Board of Directors, received $2,736,874 in total compensation for fiscal 2025. Compared with the $4,802,309 reported for fiscal 2024, Lanfear's total was 43.0% lower.
What was Coherus Oncology's say-on-pay result?
The say-on-pay proposal drew 87.1% of votes cast for or against in favor at the meeting held May 27, 2026 for fiscal 2025.
Which companies are in Coherus Oncology's peer group?
The disclosed peer group includes ACADIA Pharmaceuticals, Agenus, Agios Pharmaceuticals, Amicus Pharmaceuticals and Collegium Pharmaceuticals, among others. The 2025 Compensation Peer Group names ACADIA Pharmaceuticals, Agenus, Agios Pharmaceuticals, Amicus Pharmaceuticals and Corcept Therapeutics, among others. The new peer group (2026 compensation decisions) includes Actuate Therapeutics, Allogene Therapeutics, Black Diamond Therapeutics, Cardiff Oncology and Caribou Biosciences, among others. The Updated Peer Group includes Actuate Therapeutics, Allogene Therapeutics, Black Diamond Therapeutics, Caribou Biosciences and Corbus Pharmaceuticals, among others.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Dennis Lanfear
President, Chief Executive Officer and Chairman of the Board of Directors
◇—◇◇◇—◇◇
Vladimir Vexler
Chief Scientific Officer (5)
◇—◇◇◇—◇◇
McDavid Stilwell
Chief Financial Officer
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Dennis Lanfear
President, Chief Executive Officer and Chairman of the Board of Directors
◇—◇◇◇—◇◇
McDavid Stilwell
former Chief Financial Officer (6)
Departed during or after this year
◇—◇◇——◇◇
Vladimir Vexler
former Chief Scientific Officer (7)
Departed during or after this year
◇—◇◇——◇◇
Paul Reider
Chief Commercial Officer
◇—◇◇◇—◇◇
Bryan McMichael
Interim Chief Financial Officer (5)
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Dennis Lanfear
President, Chief Executive Officer and Chairman of the Board of Directors
◇——◇◇—◇◇
Paul Reider
Former Chief Commercial Officer
◇——◇◇—◇◇
Bryan McMichael
Chief Financial Officer
◇——◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Dennis Lanfear
President, Chief Executive Officer and Chairman of the Board of Directors
◇——◇◇—◇◇
Paul Reider
Former Chief Commercial Officer
Departed during or after this year
◇——◇——◇◇
Bryan McMichael
Chief Financial Officer
◇——◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Bryan McMichaelOPTION——————◇
Dennis LanfearOPTION——————◇
Paul ReiderOPTION——————◇
Fiscal 2022, 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Bryan McMichaelOption◇—◇1/3/2035
Option◇—◇8/7/2034
RSU◇◇——
Option◇—◇1/7/2032
Option◇—◇9/7/2032
Option◇—◇1/4/2033
Option◇—◇3/27/2033
Option◇—◇1/2/2034
Option◇—◇5/7/2035
Dennis LanfearRSU◇◇——
Option◇—◇1/4/2032
Option◇—◇1/5/2033
Option◇—◇1/5/2034
Option◇—◇1/10/2035
Option◇—◇5/7/2035
Paul ReiderRSU◇◇——
Option◇—◇1/4/2032
Option◇—◇1/4/2033
Option◇—◇1/2/2034
Option◇—◇1/3/2035
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Mats L. Wahlström
Lead independent director
◇—◇———◇
Charles W. Newton
◇—◇———◇
Ali J. Satvat
◇—◇———◇
Rita A. Karachun
◇—◇———◇
Georgia Erbez
◇—◇———◇
Michael Ryan
◇—◇———◇
Lee N. Newcomer, MD
◇—◇———◇
Jill O'Donnell-Tormey, Ph.D
◇—◇———◇
Mark D. Stolper
◇—————◇
Dennis M. Lanfear served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Total board retainer◇
Board chair premium◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • ACADIA Pharmaceuticals ACAD
  • Agenus AGEN
  • Agios Pharmaceuticals AGIO
  • Amicus Pharmaceuticals FOLD
  • Collegium Pharmaceuticals COLL
  • Corcept Therapeutics CORT
  • Deciphera Pharmaceuticals DCPH
  • Dynavax Technologies DVAX
  • Eagle Pharmaceuticals EGRX
  • Fibrogen symbol not shown
  • Heron Therapeutics HRTX
  • Intercept Pharmaceuticals ICPT
  • Ironwood Pharmaceuticals IRWD
  • Karyopharm Therapeutics KPTI
  • Mirum Pharmaceuticals MIRM
  • Nektar Therapeutics NKTR
  • Pacira BioSciences PCRX
  • PTC Therapeutics PTCT
  • Puma Biotechnology PBYI
  • Supernus Pharmaceuticals SUPN
  • Vanda Pharmaceuticals VNDA
2025 Compensation Peer Group
  • ACADIA Pharmaceuticals ACAD
  • Agenus AGEN
  • Agios Pharmaceuticals AGIO
  • Amicus Pharmaceuticals symbol not shown
  • Corcept Therapeutics CORT
  • Deciphera Pharmaceuticals DCPH
  • Dynavax Technologies DVAX
  • Eagle Pharmaceuticals EGRX
  • Heron Therapeutics HRTX
  • Ironwood Pharmaceuticals IRWD
  • Karyopharm Therapeutics KPTI
  • Mirum Pharmaceuticals MIRM
  • Nektar Therapeutics NKTR
  • Pacira BioSciences PCRX
  • PTC Therapeutics PTCT
  • Supernus Pharmaceuticals SUPN
  • Vanda Pharmaceuticals VNDA
new peer group (2026 compensation decisions)
  • Actuate Therapeutics ACTU
  • Allogene Therapeutics ALLO
  • Black Diamond Therapeutics BDTX
  • Cardiff Oncology CRDF
  • Caribou Biosciences CRBU
  • Corbus Pharmaceuticals CRBP
  • Cullinan Therapeutics CGEM
  • Lyell Immunopharma LYEL
  • Olema Pharmaceuticals OLMA
  • Perspective Therapeutics CATX
  • Pliant Therapeutics PLRX
  • Precigen PGEN
  • RAPT Therapeutics RAPT
  • Replimune Group REPL
  • Xencor XNCR
  • Zentalis Pharmaceuticals ZNTL
Updated Peer Group
  • Actuate Therapeutics ACTU
  • Allogene Therapeutics ALLO
  • Black Diamond Therapeutics BDTX
  • Caribou Biosciences CRBU
  • Corbus Pharmaceuticals CRBP
  • Cullinan Therapeutics CGEM
  • Olema Pharmaceuticals OLMA
  • Perspective Therapeutics CATX
  • Pliant Therapeutics PLRX
  • Precigen PGEN
  • RAPT Therapeutics RAPT
  • Replimune Group REPL
  • Xencor XNCR
  • Zentalis Pharmaceuticals ZNTL

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025May 27, 2026=◇◇◇
2024June 11, 2025=◇◇◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Dennis Lanfear (President, Chief Executive Officer and Chairman of the Board of Directors), FY2025 total compensation $2,736,874 (base salary $1,026,545) [exec_comp, SEC accession 0001104659-26-045251, filed 2026-04-20]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Coherus Oncology files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Coherus Oncology disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Coherus Oncology sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Coherus Oncology's disclosed peer group is defensible, who names Coherus Oncology back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
162 figures on this page: 160 cited to the filing that reported them, 2 calculated from figures it prints.
160 cited to the filing
2 calculated from the filing

Documents cited

  1. 0001104659-26-068615
  2. 0001104659-26-045251
    NON-EMPLOYEE DIRECTOR COMPENSATION · Summary Compensation Table
  3. 0001104659-25-059351
  4. 0001558370-24-005131
    EXECUTIVE COMPENSATION TABLES
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Coherus Oncology executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/CHRS (accessed 2026).
Short form: data: Velarion

The Coherus Oncology brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
4 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Coherus Oncology and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Coherus Oncology discloses

The companies named in CHRS's own disclosed peer group.

ACADIA PharmaceuticalsAgenusAgios PharmaceuticalsAmicus PharmaceuticalsCollegium PharmaceuticalsCorcept TherapeuticsDeciphera PharmaceuticalsDynavax TechnologiesEagle PharmaceuticalsHeron TherapeuticsIntercept PharmaceuticalsIronwood PharmaceuticalsKaryopharm TherapeuticsMirum PharmaceuticalsNektar TherapeuticsPacira BioSciencesPTC TherapeuticsPuma BiotechnologySupernus PharmaceuticalsVanda PharmaceuticalsActuate TherapeuticsAllogene TherapeuticsBlack Diamond TherapeuticsCardiff Oncology

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy